DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Meta Expands AI Training With Employee Activity Tracking Tools 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
HOPKINTON, Mass., May 22, 2017 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, cancer, and inflammatory diseases, announced today that the company’s management team plans to host a conference call on Wednesday, May 24, 2017, at 8:00 a.m. ET, to discuss top-line results from the initial 25mg monotherapy dosing cohort of the Phase 2a segment of its ACHIEVE trial, a global, placebo-controlled, sequential-cohort, double-blind Phase 2 clinical trial for chronic Hepatitis B virus (HBV).
The conference call may be accessed by dialing (866) 294-9216 for U.S. callers and (346) 406-0955 for international callers five minutes prior to the start of the call and providing the conference ID: 27754723. Additionally, the live, listen-only webcast of the conference call can be accessed by visiting the Investors & Media section of the Company’s website at www.springbankpharm.com. A replay of the conference call will be available following the call and may be accessed by visiting Spring Bank’s website.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV). SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body's immune response to viral infections. Spring Bank Pharmaceuticals is also developing other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway. For more information, please visit www.springbankpharm.com
Contact: Spring Bank Pharmaceuticals, Inc. Jonathan Freve Chief Financial Officer (508) 473-5993 [email protected]
